Fokus

Jörgen mejlar och tycker vi ska fokusera på annat än nyemissionen. Och det har han helt rätt i.

First half-year 2025

• Initiation of a QMS System allowing for the development of a clinical HoloMonitor® version
• The upgraded HoloMonitor® version ready for the (pre-clinical) market

Utöver detta är det bara att lusläsa bloggen om alla eventuella triggers som kan sätta sprutt på både aktien som humöret. PHI`s ingång i T-Cell området gäckar fortfarande. Kommer nästan dagligen nya rapporter om vad kroppens eget immunförsvar tillsammans med forskarnas "omprogrammering" av dessa celler kan göra. 
Ska leta upp 1 och lägga ut här på bloggen så ni börjar fatta vidden av de nya möjligheterna att bota extremt svåra sjukdomar,främst cancer då det området är så stort och tyvärr växande.

Kommer här:

CAR-T Cell och barn med obotlig hjärncancer. Men kanske inte obotlig så värst länge till? Läs nedanstående artikel och bli imponerade.

54 forskare från amerikanska Stanford har nått ett genombrott vid stopp av en jävligt jobbig hjärncancer (glioma) för barn. Stanford är ett HoloMonitorUniversitet kan vara intressant att veta.  Länk

CAR-T Cell Therapy, Illustration. A T-lymphocyte white blood cell (blue) attacking a cancer cell (red). [Nemes Laszlo/Science Photo Library/Getty Images]

Clinical trial results are showing the first successes against solid tumors for CAR-T cells. The findings offer hope for children with a group of deadly brain and spinal cord tumors, including a cancer called diffuse intrinsic pontine glioma, or DIPG. The immune-cell therapy shrank children’s brain tumors, restored neurologic function and—for one participant—erased all detectable traces of a brain cancer typically considered incurable.

Of the 11 participants who received CAR-T cells in the trial, nine showed benefits and had functional improvement in the disabilities caused by their disease. Four participants had the volume of their tumors reduced by more than half and one of those four participants had a complete response (meaning his tumor disappeared from brain scans). Although it is too soon to say whether he is cured, he is healthy four years after diagnosis.

“This is a universally lethal disease for which we’ve found a therapy that can cause meaningful tumor regressions and clinical improvements,” said Michelle Monje, MD, PhD, professor of neurology at Stanford Medicine. “While there is still a long way to go to figure out how to optimize this for every patient, it’s very exciting that one patient had a complete response. I’m hopeful he has been cured.” The patient, 20-year-old Drew, wants his outcome to be the first of many. “I’m hoping they’ll learn from all my successes to help other kids,” he said.

Studien är publicerad i Nature som sig bör.

Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas

Det framgår inte om forskarna använt sig av sitt HoloMonitorinstrument är värt att påpeka.

                                              Mvh the99

Tungt

Så känner nog de flesta phi,are just nu,ink undertecknad.Med ett börsvärde under 50 Msek är aktien fullständigt massakrerad. Så vad göra nu såna här pixxdagar? Låta bli att kolla depån för att inte deppa ihop totalt är väl det som jag närmast kommer på.Man får försöka härda ut tills emissionen är överstökad och krutröken lagt sig. 
Sen därefter med en välfylld kassa och ett skuldfritt PHI är det bizznizz as usual och dags att se framåt. Förhoppningsvis kommer Altiumgänget + den HoloMonitorförsäljningsdedikerade Daniel Soor att börja leverera glädjepiller i form av riktigt bra instrumentförsäljningar. Annat vore extremt förvånande. Sen har vi fortfarande allt som ligger i pipelinen kvar att räkna hem. Så pallar man med nuvarande läge ett tag till kommer en återhämtning som återställer det momentum vi haft för inte så länge sen.

Och apropå nyemissioner.Jag tycker det vimlar av dessa när jag kollar mina bevakningslistor över framförallt småbolagen. Pågående som nyligen avslutade kassapåfyllningar.PHI är alltå inte ensamt om detta impopulära fenomen. Till PHI´s fördel gentemot majoriteten av andra är att de har en storägare som tror på Bolaget och går in och garanterar i princip hela emissionen. Tillsammans med ett gäng övriga garanter kommer PHI`s nyemission bli fylld till 100%. Få andra småbolag kan visa upp det. Så vi ska nog vara tacksamma att ha Altium vid vår sida.

Sen kan det vara bra att veta att börsen är riktigt skakig rent allmänt just nu. Osäkerhet råder efter Trump som ny president. Ska han införa tullar som kan slå hårt mot den europeiska industrin samt alla svenska företag som har affärer med USA är det som spökar i bakgrunden. Osäkerhet är börsens nemesis och inget den gillar. 
Andra omvärldsfaktorer som risk för eskalering av Ukraina-Ryssland eländet är som extra lök på laxen då.

I övrigt fortsätter yours truly att dammsuga nätet på relevant info att lägga upp på bloggen. 
Hittar ni andra phi-grävare intressant info är det bara att mejla över så kollar jag vidare på den.

                                               Mvh the99

Söndagsmix

Består idag av 2 bidrag från vassa phi-grävare och ett litet gräv jag gjort själv. Från gårdagens kommentarsbås får vi info att Glycoprojektet utvecklats vidare till förfining av MIP,sarna förmåga att identifiera ytskikt på avsedda mål (cancerceller). Knut Rurack et al. har utgått från resultaten av föregående studier som redovisas här. 
I denna nya studie berättar man hur MIP,sarna utrustats med molekyler som ingår i nåt som kallas BODIPY. 

Wiki berättar mera: BODIPY är det tekniska vanliga namnet på en kemisk förening med formel C9H7BN2F2, vars molekyl består av en grupp bor difluorid BF2. 

Förenad med en dipyrrometengrupp C9H7N2; närmare bestämt föreningen 4,4-difluoro-4-bora-3a,4a-diaza-s-indacen i IUPAC-nomenklaturen.Det vanliga namnet är en förkortning för "bor-dipyrrometen". 

Det är ett rött kristallint fast ämne, stabilt vid omgivningstemperatur, lösligt i metanol.
Själva föreningen isolerades först 2009,men många derivat – formellt erhållna genom att ersätta en eller flera väteatomer med andra funktionella grupper – har varit kända sedan 1968 och utgör den viktiga klassen av BODIPY-färgämnen.Dessa organoborföreningar har väckt stort intresse som fluorescerande färgämnen och markörer inom biologisk forskning. /
Glasklart va? 😎 Men till studien:

Ratiometric Molecularly Imprinted Particle Probes for Reliable Fluorescence Signaling of Carboxylate-Containing Molecules

 Abstract

In addition to sensitivity, selectivity, and portability, chemical sensing systems must generate reliable signals and offer modular configurability to address various small molecule targets, particularly in environmental applications. We present a versatile, modular strategy utilizing ratiometric molecularly imprinted particle probes based on BODIPY indicators and dyes for recognition and internal referencing. Our approach employs polystyrene core particles doped with a red fluorescent BODIPY as an internal standard, providing built-in reference for environmental influences. A molecularly imprinted polymer (MIP) recognition shell, incorporating a green-fluorescent BODIPY indicator monomer with a thiourea binding site for carboxylate-containing analytes, is grafted from the core particles in the presence of the analyte as the template. The dual-fluorescent MIP probe detects fexofenadine as the model analyte with a change in green emission signal referenced against a stable red signal, achieving a detection limit of 0.13 μM and a broad dynamic range from 0.16 μM to 1.2 mM, with good discrimination against other antibiotics in acetonitrile. By selecting a versatile dye scaffold and recognition element, this approach can be extended to other carboxylate-containing analytes and/or wavelength combinations, potentially serving as a robust multiplexing platform. 

Introduction

Fluorescence analysis is a powerful technique for (bio)chemical sensing due to its high sensitivity, fast acquisition times, adaptable instrumentation, and versatility in using various luminescent materials, including quantum dots (QDs), metal–organic frameworks (MOF), metal nanoclusters, and organic dyes.Among organic dyes, boron-dipyrromethene (BODIPY) dyes stand out for their brightness, photostability, spectral tunability and synthetic versatility, allowing for the integration of a large number of functional substituents. BODIPYs are thus ideal candidates for fluorescent indicators or molecular probes in detecting a range of analytes such as metal ions, biologically active thiols or reactive oxygen, nitrogen and sulfur species.

Min kommentar
Som jag förstår det har Knut med kollegor förfinat och anpassat MIP,sarna så att med fluotekniken kan dessa MIP,sar näppeligen missa att identifiera sina mål som bör vara jobbiga cancerceller beskrivna i mitt tidigare inlägg. Vad som återstår för att beskriva Glycoprojektet 100% klart och färdigt för nästa steg vet förmodligen bara dessa forskare. 

Men att vi kommit ett steg närmare en kommersialieringseringsfas kan vi nog utgå ifrån. 

Att tillägga är att med denna förbättring ökar rimligtvis värdet på Glyco då tekniken visar på minutiös detektering där få/inga? cancerceller undgår MIP,sarnas sök. Förhoppningsvis ökar även bjässarnas intresse för att sno åt sig Glyco innan tekniken uppmärksammas alltför stort.

--------------------------------------------------------------------------

I mejlkorgen berättar en phi,are om en ny forskningsartikel författad av 4 japanska forskare. Studien handlar om hudcellers förmåga till sårläkning (Wound Healing) efter en skada. Som de flesta phi,are vet är HoloMonitor ypperlig att använda med assay:en Wound Healing With Single-cell Tracking vid sådana studier.  Men till studien:

FoxO3a Plays a Role in Wound Healing by Regulating Fibroblast Mitochondrial Dynamics

ABSTRACT

The skin plays a protective role against harmful environmental stress such as ultraviolet rays. Therefore, the skin is constantly exposed to potential injuries, and wound healing is a vital process for the survival of all higher organisms. Wound healing is dependent on aging and metabolic status at a whole-body level. Because the forkhead box O (FOXO) family plays a role in aging and metabolism, we investigated the molecular functions of FOXO3a in skin wound healing using FoxO3a−/− mice. We observed that FoxO3a−/− mice showed accelerated skin wound healing. During wound healing, more fibroblasts accumulated at the wound edges and migrated into the wound bed in FoxO3a−/− mice. Moreover, cell migration of dermal fibroblasts isolated from FoxO3a−/− mice was significantly induced. During the in vitro cell migration, we observed accelerated mitochondrial fragmentation and decreased oxygen consumption in the mitochondria of FoxO3a−/− fibroblasts. These changes were caused by the upregulation of mitochondrial Rho GTPase 1 (Miro1), which is an essential mediator of microtubule-based mitochondrial motility. Miro1 inhibition significantly attenuated cell migration, mitochondrial fragmentation, and mitochondrial recruitment to the leading edge of the cells. These data indicate that FoxO3a plays a crucial role in wound healing by regulating mitochondrial dynamics.

MATERIALS AND METHODS (urval)

Cell migration assay

Cells were seeded into a 2-well silicone insert (ibidi GmbH, Gräfelfing, Germany) and grown for 24 h. 
The inserts were then removed using sterile tweezers, resulting in a 500 μm-wide gap. 
Phase-holographic imaging of live unlabeled cells was performed using the digital phase-holographic imager HoloMonitor M4 (Phase Holographic Imaging PHI AB, Lund, Sweden). 
The cells were imaged every hour with at least three different fields of view per dish. 
The holographic images were analyzed using HStudio 2.7 (Phase Holographic Imaging PHI AB).

Min kommentar
De japanska forskarna har studerat hud som varit kraftigt exponerat för ultraviolett strålning (solning) och tagit skada. Hur hudens förmåga till läkning sker innan en ev hudcancer uppstår som följd av skadan. En nog så viktig kunskap för att förebygga en hudcancer. Återigen visar HoloMonitor sin användbarhet inom cancerns område.

------------------------------------------------------------------------------

PHI har utökat sin närvaro i Kina genom att finnas med i återförsäljaren TekonBiotech´s utbud.

Tekon beskriver sin verksamhet enligt följande : We sell and support a broad range of technologies for the China life sciences market. Tekon’s customers include major pharmaceutical companies, biotech companies and universities. Tekon is headquartered in Shanghai.

Här hittar man Tekons infosida om HoloMonitor.
Nånting säger mig att Altium ligger bakom denna utvidgning. HoloMonitor är här i fint sällskap med andra företags cellinriktade produkter.

                                                Mvh the99

Nytt på Reg Med fronten

Lupus eller som vi i Sverige kallar den SLE (Systemisk Lupus Erythematosus) är en besvärlig autoimmun inflammationssjukdom det inte finns någon bot för. Bäraren kan drabbas av blodproppar med risk för stroke eller organsvikt där bägge i värsta fall leder till xxx. 1177 kan berätta mer om Lupus.

Men hav förtröstan om du skulle ha oturen att drabbas av Lupus. Forskare inom Reg Med har testat CAR T-cells behandling på Lupuspatienter,med förbluffande resultat. Ur en googleöversatt artikel kan man inledningsvis läsa :

A ‘Crazy’ Idea for Treating Autoimmune Diseases Might Actually Work

Lupus has long been considered incurable—but a series of breakthroughs are fueling hope.

Läkare brukar säga att lupus inte påverkar två patienter på samma sätt. Sjukdomen gör att immunförsvaret blir galet på ett sätt som kan slå mot i stort sett vilket organ som helst i kroppen, men när och var är galet svårfångat. En patient kan ha sår i ansiktet, som liknades vid vargbett av 1200-talsläkaren som gav lupus dess namn. En annan patient kan ha njursvikt. En annan, vätska runt lungorna. Vad läkarna kan säga till varje patient är dock att de kommer att ha lupus resten av livet. Ursprunget till autoimmuna sjukdomar är ofta mystiska, och ett immunsystem som ser kroppen den bor i som en fiende kommer aldrig att slappna av helt. Lupus kan inte botas. Ingen autoimmun sjukdom kan botas.

För två år sedan kom dock en studie från Tyskland som skakade om alla dessa antaganden. Fem patienter med okontrollerad lupus gick i fullständig remission efter att ha genomgått en återanvänd cancerbehandling som kallas CAR-T-cellsterapi, vilket till stor del utplånade deras oseriösa immunceller. Den första behandlade patienten har inte haft några symtom på nästan fyra år nu. "Vi vågade aldrig tänka på botemedlet mot vår sjukdom", säger Anca Askanase, en reumatolog vid Columbia Universitys medicinska center som specialiserat sig på lupus. Men de här häpnadsväckande resultaten – remission hos alla patienter – har gett bränsle åt en ny våg av optimism. Mer än 40 personer med lupus världen över har nu genomgått CAR-T-cellsterapi, och de flesta har gått i läkemedelsfri remission. Det är för tidigt att förklara någon av dessa patienter botade för livet, men det verkar nu vara möjligt.

Utöver lupus hoppas läkarna att CAR-T förebådar ett större genombrott mot autoimmuna sjukdomar, vars förekomst har ökat oroväckande. CAR-T har redan använts experimentellt för att behandla patienter med andra autoimmuna sjukdomar, inklusive multipel skleros, myosit och myastenia gravis. Och framgången med CAR-T har inspirerat forskare att låna andra – billigare och enklare – strategier från cancerterapi för att döda immunceller som gått snett. Alla dessa idéer kommer inte att slå igenom, men om någon gör det kan de närmaste åren innebära en vändpunkt i behandlingen av några av de mest frustrerande och svårbehandlade sjukdomarna i vår moderna tid.

-------------------------------------------------------------------------------

Amerikanska Reg Med forskare har möjligtvis hittat,inte en bot mot Alzheimer men möjligheter att fördröja sjukdomens förlopp med 10-15 år. Det via en stamcellsformula som distribueras via en nässpray. 

Nasal Spray Made From Stem Cell-Derived Vesicles Could Treat Alzheimer’s Disease

Research from the College of Medicine offers hope for delaying Alzheimer’s disease progression by years after initial diagnosis.

Lead researcher Ashok Shetty has filed a patent on the intranasal application of neural stem cell-derived extracellular vesicles for treating Alzheimer’s and other neurological and neurodegenerative disorders.

A new therapy may delay Alzheimer’s disease progression by years, according to a study by researchers at Texas A&M University College of Medicine. Published in the Journal of Extracellular Vesicles, the research aims to explore treatment options for Alzheimer’s, which constitutes the most common form of dementia and is a leading cause of death among those aged 65 or older, afflicting nearly 7 million Americans.

Utilizing a nasal spray to non-invasively target cells perpetuating chronic neuroinflammation, researchers found decreased inflammation in the brain and a reduction in the build-up of plaques and proteins thought to be linked to the progressive loss of neurons in the brain, characteristic of Alzheimer’s.

“This approach is effective because the cargo carried by these extracellular vesicles could reduce the neuropathological changes in the brain,” says Ashok K. Shetty, Ph.D., a University Distinguished Professor and associate director at the Institute for Regenerative Medicine in the Department of Cell Biology and Genetics.

“Our journey to advance the application of this therapy for Alzheimer’s disease is just beginning,” säger forskaren.

----------------------------------------------------------------------------------

Delstaten New York storsatsar för att möta upp Reg Med klustret i North Carolina, Winston-Salem där WFIRM med ReMDO har sitt center. Länk

$430 Million Project Will Catalyze Research, Development, and Commercialization of Life-Saving Therapies

State's $150 Million Commitment Marks Largest State Investment in Cell and Gene Therapy Nationwide

Advances New York's Statewide Vision for Cell and Gene Therapy Leadership

Governor Kathy Hochul today unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

“With this groundbreaking hub, New York has the opportunity to stake its claim as the epicenter of cell and gene therapy innovation,” Governor Hochul said. “We're not just advancing medical science; we're creating a powerhouse that will drive our economy, generate thousands of high-skilled jobs, and bring hope to millions facing life-threatening diseases. This investment reaffirms our commitment to leading the future of healthcare and ensuring that the next medical breakthrough happens right here in New York.”

Är vår man i USA på tårna och snabb i vändningarna kanske PHI kan muta in denna hubb som HoloMonitorland? Håkan,har du packat resväskan och bokat en flygbiljett till The Big Apple? 😎

Eller aproacha denna hubb samtidigt som PHI träffar amerikanska investerare nästa vecka 20/11,just i New York? Länk

Min kommentar
Till alla deppiga phi,are : cheer up. Reg Med kakan jäser så det knakar i USA och PHI har alla möjligheter att ta en tugga av den. Med Altiums recept för att knåda deg (göra affärer) vore det ju fasiken om vi inte lyckas där (för att travestera en känd New York låt med "Old Blue Eyes". Fusksvar

                                                    Vid pennan eder The99

Bloggens syn på nyemissionen

> PHI har beslutat om en fullt säkerställd företrädesemission om 64,3 Msek <

Vi börjar med det konstaterandet. Oavsett om ingen av oss aktieägare tecknar några nya aktier kommer PHI få emissionen fylld och 64,3 Msek före kostnader in i kassan. Låt det sjunka in för ett tag.

PHI`s börsvärde just nu är på ca 54 Msek. Det vid en aktiekurs på 2 kr. Nyemissionens kurs är på 1,80.

Så frågan man ska ställa sig är varför sälja aktier när det enbart diffar 20 öre om man väljer att inte teckna sig för nya? De som säljer av sitt innehav nu kommer inte ha TR som ger möjlighet att köpa för 1,80.
Alltså kliver de av helt från PHI vilket får accepteras.Förståeligt sett i skenet av den usla kursutveckling som varit. 
Dock måste förlusten i kr bli högst kännbar om man haft lite större innehav med GAV närmare eller över 10 kr. 

Vi går tillbaka till att emissionen är fullt säkerställd,garanterad att stärka PHI`s kassa med 64,3 Msek före kostnader. Vad händer sen när kassan är påfylld och emissionen överstökad?

Rimligtvis kommer det ge en kraftig reaktion uppåt för aktien. Varför? Jo av 2 skäl. 

1. När det sjunker in för alla att PHI är skuldfritt och har en välfylld kassa är de mörka molnen borta och vi kan återgå till att se vad som ligger framför oss. De som följt bloggen är väl uppdaterade på den fronten.

2. Eftersom emissionen är garanterad till 100% kommer vi inte se några ev kortsiktiga garanter sälja sina aktier till bäst-pris,dvs ner till rena botten-botten nivåer vilket ofta är fallet när en nyemission inte blir fulltecknad. 

I detta fallet tror jag de ev kortsiktiga garanterna ev kommer börja avyttra sina aktier först vid 3-4 kr.

Jag grundar det på följande : aktien handlades mellan 5-6 kr innan vi i Sep fick beskedet att TO4 fastställdes till 4,63 kr. Det fick ner aktien till låga 5 kr.Efter inlösen av optionen började vi sakta dippa ner mot låga 4 kr. 

Vi har alltså ett gap att fylla till i första hand 5 kr.Det har säkert även garanterna listat ut.
Därför tror jag att de ev kortsiktiga garanterna ev kommer börja avyttra aktier först vid 3-4 kr. 

Den större positionen lär krängas först när vi passerar 5 kr.

OBS! Det här är enbart mina egna tankar och ingen utfästelse att så kommer ske.

Frågan kvarstår,varför sälja sina aktier till 2 kr?

Altium då? De kommer ställa upp med ca 35,7 Msek (15,2 + 20,5 Msek) i emissionen enligt utfästelse.

Men eftersom de aviserar en top-down garanti på 100% kan man tolka det som att de garanterar hela emissionen om de övriga garanterna kliver av. Alltså ingen befarad nerkörning i kursen efter emissionen.

Altium har dessutom ett lock-up avtal i denna emission att de inte kommer sälja några aktier inom 6 månader efter emissionen är överstökad.

Farhågor för att Altium får för stort innehav och köper loss PHI till småpengar?

Nix pix,never gonna happen.

Altium har visat att det inte kommer ske nånting åt det hållet efter denna emission, där de blir majoritetsägare med innehav som förpliktar till ett bud enligt börsens regelverk.

"Altium har av Aktiemarknadsnämnden beviljats dispens från budpliktskraven om dess aktieinnehav skulle uppgå till eller överstiga 30 procent av antalet röster i Bolaget med anledning av Altiums deltagande i Företrädesemissionen."

De har alltså redan begärt att slippa lägga ett bud i vetskap om att de kommer ha över 30% av aktierna efter emissionen.

Vill de senare ändå kapa åt sig PHI för egen del krävs det ett aktieinnehav på minst 90% av totalen för att de ska kunna tvångsinlösa Bolaget. 90% = Never Gonna Happen.

Seriösa tankar på ovanstående? Har ni ett annat tänkvärt scenario kopplat till emissionen,under och efter den är överstökad så delge det gärna. Mvh the99

Ps. Ni har väl läst mitt föregående inlägg om hudcancer där jag jämför dagens tidsåtgång för diagnos mot vad forskarna berättar om, 2 veckor i labb mot 58 timmar vid HoloMonitor. Väl förvaltat av PHI kan denna nya kunskap bli en blockbuster.

HoloMonitor gör skillnad

I en studie publicerad för 2 dagar sen, 11/11, visar forskare från University of Michigan-Dearborn

att HoloMonitor kan särskilja mellan vanliga och ofarliga hudceller (melanocyter) och aggressiva hudcancerceller (SK-MEL-28 Melanoma Cells). Upptäckten har betydelse för framtida bättre och snabbare diagnosställning samt behandling av en aggressiv hudcancer.

Morphological and Optical Profiling of Melanocytes and SK-MEL-28 Melanoma Cells Via Digital Holographic Microscopy and Quantitative Phase Imaging

Abstract

Melanoma, which originates from pigment-producing melanocytes, is an aggressive and deadly skin cancer. Despite extensive research, its mechanisms of progression and metastasis remain unclear. This study uses quantitative phase imaging via digital holographic microscopy, Principal Component Analysis (PCA), and t-distributed Stochastic Neighbor Embedding (t-SNE) to identify the morphological, optical, and behavioral differences between normal melanocytes and SK-MEL-28 melanoma cells. Our findings reveal significant differences in cell shape, size, and internal organization, with SK-MEL-28 cells displaying greater size variability, more polygonal shapes, and higher optical thickness. Phase shift parameters and surface roughness analyses underscore melanoma cells' uniform and predictable textures. Violin plots highlight the dynamic and varied migration of SK-MEL-28 cells, contrasting with the localized movement of melanocytes. Hierarchical clustering of correlation matrices provides further insights into complex morphological and optical relationships. Integrating label-free imaging with robust analytical methods enhances understanding of melanoma's aggressive behavior, supporting targeted therapies and highlighting potential biomarkers for precise melanoma diagnostics and treatment.

1 Introduction

Melanoma is a highly aggressive form of skin cancer originating from melanocytes, the pigment-producing cells in the epidermis.Despite extensive research, the biological mechanisms underlying melanoma progression and metastasis remain incompletely understood, necessitating more detailed studies on cellular morphology, behavior, and molecular characteristics.

Morphological analysis using advanced imaging techniques can provide critical insights into the structural differences between normal melanocytes and SK-MEL-28 melanoma cells.
These differences are pivotal for understanding the disease and developing targeted therapeutic strategies.Recent advances in holographic microscopy have enabled detailed visualization of cellular structures, revealing significant differences in cell shape, size, and internal organization.These imaging techniques allow for the examination of parameters such as cell area, optical volume, and thickness, offering a comprehensive view of cellular morphology.

This study aims to characterize the morphological, optical, and behavioral differences between normal melanocytes and SK-MEL-28 melanoma cells using advanced imaging and analytical techniques. By leveraging 2D and pseudo-3D microscopy, PCA, t-SNE, and cell movement analysis, we seek to elucidate the distinct features of melanoma cells that contribute to their aggressive behavior and potential for metastasis. The findings from this research provide valuable insights that could inform the development of more effective diagnostic and therapeutic strategies for melanoma.

HoloMonitor visar här skillnaderna mellan dessa 2 celltyper.

Holographic Microscopic Images A) and Single Cell Thickness Measurements Across Length and Width B) of Melanocytes and SK-MEL-28 cells.

Cell Culture and Digital Holographic Microscopy

The melanoma cell line SK-MEL-28 (ATCC HTB-72) was cultured in RPMI 1640 (ATCC 30–2001) supplemented with 10% Fetal Bovine Serum (ATCC) and 1% Penicillin-Streptomycin (Thermo Fisher) at 37 °C with 5% CO2. Primary epidermal melanocytes (HEMa, ATCC PCS-200-013) were cultured in Dermal Cell Basal Medium (ATCC PCS-200-030) combined with the Adult Melanocyte Growth Kit (ATCC PCS-200-042) at 37 °C with 5% CO2, with the complete growth medium containing 5 µg mL−1 rh Insulin, 50 µg mL−1 Ascorbic Acid, 6 mM L-Glutamine, 1.0 µM Epinephrine, 1.5 mM Calcium chloride, 0.2% Peptide Growth Factor (proprietary formulation), and 1% M8 Supplement (proprietary formulation). Both cell lines were seeded in 24-well plates and analyzed over a 58-h period using a HoloMonitor M4 holographic imaging microscope (Phase Holographic Imaging, Lund, Sweden). The HoloMonitor M4 captured images at 15-min intervals in each well, with each interval consisting of 30 frames. The App Suite Cell Imaging software analyzed these frames, conducting Guided End-Point Assays (including Cell Quality Control), Guided Kinetic Assays (including Kinetic Proliferation Assay and Kinetic Motility Assay), and In-Depth Assays (including Cell Morphology), providing detailed insights into cell behavior and morphology over the observation period.

2D, pseudo 3D Cell Holographic Microscopy

Microscopic 2D images of the Melanocytes and SK-MEL-28 cells were captured via the HoloMonitor M4, which automatically snapped photos of the cells at 15-min intervals over a 58-h time period. Under the “Experiment Overview” feature of the App Suite Cell Imaging software, the image color palette was modified via the Coloring panel from a monochromatic scale to a blue-yellow coloring, with the blue indicative of the cells and the yellow indicative of the growth medium. The colors applied were relative to the thickness of the cells, with the scale ranging from -0.5 µm to 20.1 µm.

Individual pseudo-3D images of the Melanocytes and SK-MEL-28 cells were analyzed via the App Suite Cell Imaging software of the HoloMonitor M4.

Cell Movement Plot

In order to identify patterns of cell movement over time between Melanocytes and SK-MEL-28 cells, the movement of the cells in their respective wells on a Cell Movement Plot was visualized. The analysis was completed using the App Suite Cell Imaging software of the HoloMonitor M4. Using the “In-Depth Analysis: Single Cell Tracking” package of the software, 235 frames of the wells containing viable cells, which were taken at 15-min intervals, via the “Identify Cells” function were analyzed. These frames were then applied to the “Single Cell Tracking” function and integrated into an analysis to track cell movements across a 58-h period. Every cell in the well under the “Cell Movement Plot” feature, thus ensuring that each cell was incorporated into the plot was opted to include.

3 Discussion

Quantitative phase imaging (QPI) has become a formidable technique for characterizing cells without the need for labels, utilizing the principles of digital holographic microscopy (DHM) to offer comprehensive insights into cellular morphology and dynamics. In the last twenty years, there have been notable advancements in QPI methods, which have broadened their use in cell biology. Various QPI methodologies have been developed highlighting their dependability and quantitative mapping capabilities.These advancements have streamlined the use of interference microscopy, making it more accessible for biological applications. Quantitative Phase-Digital Holographic Microscopy (QP-DHM) has the potential to non-invasively visualize cellular structures and monitor dynamic processes, such as neuronal activity and spine dynamics, which are crucial for understanding cellular functions in neuroscience and psychiatry.Additionally, advancements in QPI have shown how specific biophysical parameters can be extracted from quantitative phase signals, offering critical biological insights for cell characterization.Despite these advances, challenges remain in interpreting quantitative phase signals in relation to biological processes. Accurately determining parameters such as absolute cell volume and membrane fluctuations is essential for furthering our understanding of cellular behavior.This body of work addresses these challenges by employing advanced numerical algorithms to enhance the classification and characterization of cells based on their morphological and physical properties. The novelty of this approach is the integration of a commercial DHM QPI system with advanced numerical techniques, allowing for more accurate cell classification. Deriving specific biophysical parameters and correlating them with cellular functions contributes to the development of quantitative microscopy and opens new avenues for research in cell biology and related fields.

Min kommentar
Jag kommer osökt att tänka på ett av mina besök hos min hudcancerläkare där ett misstänkt melanom skars bort och skickades till patologen för att få svar på om/hur aggressivt det var. Det tog labbet ca 2 veckor att få fram det svaret. Forskarna visar här i denna studie att de med HoloMonitor kan få fram ett första preliminärt svar på 58 h. Femtioåtta timmar!!!

Med en dåres envishet har jag,och fortsätter, hävda att HoloMonitor är ett excellent instrument för forskare (snart även kliniker) att använda vid cellforskning/studier. Denna ,snart stort uppmärksammade, studie ger mig än mer bränsle att fortsätta hävda det. Kan nu Altiums försäljningskår bli lika övertygade om HoloMonitors förträfflighet som undertecknad kanske de kan lägga på ett extra kol och börja kränga volym av instrumentet? Mvh the99

Som service till alla HoloMonitornyfikna forskare : HoloMonitor Demo

Ljus i mörkret

PHI toppar kanske inte populäritetslistan just nu,men HoloMonitor ligger iaf i topp hos de initierade.

Studien är tyvärr hårt inlåst så vi får hålla till godo med ovanstående och ett abstract. Länk

Methods to Investigate Cell Migration

• First Online: 13 November 2024

Abstract

Cell migration is of great relevance to researchers studying development, wound healing, the immune system and its responses and diseases associated with deregulated cell migration. The study of cell migration has been made possible by the development of a huge variety of experimental set-ups in 2D and 3D focussing on specific aspects of cell migration. In this chapter, some of such specific aspects of cell migration will be discussed and the assays available to investigate the particular features of cell migration. Examples of traditional cell migration assays and most recent developments ranging from wound healing assays to microfluidics studies will be given, followed by commonly used assays in a 3D setting and finally highly specialised intravital in vivo research. The advantages and disadvantages of such assays are highlighted.

Mer från Springer/Nature : 

KHDRBS1 regulates the pentose phosphate pathway and malignancy of GBM through SNORD51-mediated polyadenylation of ZBED6 pre-mRNA 

• Published: 08 November 2024

Abstract

Glioblastoma is one of the most common and aggressive primary brain tumors. 

The aberration of metabolism is the important character of GBM cells and is tightly related to the malignancy of GBM. We mainly verified the regulatory effects of KHDRBS1, SNORD51 and ZBED6 on pentose phosphate pathway and malignant biological behavior in glioblastoma cells, such as proliferation, migration and invasion. KHDRBS1 and SNORD51 were upregulated in GBM tissues and cells. But ZBED6 had opposite tendency in GBM tissues and cells. KHDRBS1 may improve the stability of SNORD51 by binding to SNORD51, thus elevating the expression of SNORD51. More importantly, SNORD51 can competitively bind to WDR33 with 3’UTR of ZBED6 pre-mRNA which can inhibit the 3’ end processing of ZBED6 pre-mRNA, thereby inhibiting the expression of ZBED6 mRNA. ZBED6 inhibited the transcription of G6PD by binding to the promoter region of G6PD. Therefore, the KHDRBS1/SNORD51/ZBED6 pathway performs an important part in regulating the pentose phosphate pathway to influence malignant biological behavior of GBM cells, providing new insights and potential targets for the treatment of GBM.

Materials and Methods (urval)

Cell migration assay

Cells were inoculated onto 6-well plates (Corning, NJ, USA) at appropriate amount and cultured under HoloMonitor M4 system for observation. 

I The effect of KHDRBS1 knockdown on cell migration of U251 and U373 cells was analyzed by Hstudio M4 system. Scale bars: 100 µm.

F The effect of SNORD51 on cell migration of U251 and U373 cells was analyzed by Hstudio M4 system. Scale bars: 100 µm.

H The combined effects of KHDRBS1 and SNORD51 on cell migration of U251 and U373 cells was analyzed by Hstudio M4 system. Scale bars: 100 µm.

                                                  Mvh the99

Som service till alla HoloMonitornyfikna forskare : HoloMonitor Demo

PHI - Nyemission

Phase Holographic Imaging PHI

PHI resolves on a fully secured rights issue of shares of approximately SEK 64.3 million (Cision)

2024-11-12 21:49

The Board of Directors of Phase Holographic Imaging PHI AB ("PHI" or the "Company") has today resolved on a rights issue of shares, with preferential rights for the Company’s existing shareholders, of approximately SEK 64.3 million before deduction of issue related costs, subject to approval by the extraordinary general meeting to be held on 2 December 2024 (the "Rights Issue"). The purpose of the Rights Issue is to fund a strategic development plan and to strengthen the Company's capital structure by repayment/off-setting of outstanding loans. The Rights Issue is secured in writing by the main shareholder Altium SA (“Altium”) and a consortium of external qualified underwriters through pre-subscription- and underwriting commitments, totalling 100 percent. Altium has entered into a customary lock-up agreement corresponding to 100 percent of Altium’s shareholdings for a period of six months following the Rights Issue. Notice for the extraordinary general meeting will be published through a separate press release. In connection with the Rights Issue, PHI has engaged Navia Corporate Finance AB as the financial advisor and Sole Bookrunner.

Goran Dubravčić, Chairman of PHI and CEO of Altium, comments

“As Chairman of the Board of PHI and CEO of Altium, I am pleased to announce Altium’s continued strong commitment and support for PHI in connection with the capitalization. We view this rights issue as an important step in supporting the company in its growth journey, particularly in light of the strong shared vision we have for driving PHI’s global expansion. Our long-term strategy has always been to actively support the company, and as both the largest shareholder and global distribution partner of PHI, we play a key and strategically important role. Through our global distribution agreement, we are responsible for driving the sales and establishing PHI's products in markets around the world. This agreement is a key component of our joint strategy to maximize PHI’s global reach and business opportunities.

As a testament to our commitment, we will be participating extensively in the rights issue and make a substantial investment, which further strengthens our partnership and trust in PHI. We believe in the company’s potential and in the positive impact our global distribution agreement will have in accelerating growth internationally. We look forward to continuing to drive success for PHI through a strong partnership built on our long-term commitment and our shared vision to capture global markets. The rights issue provides the necessary resources to ensure PHI’s continued development and create value for both shareholders and our partners worldwide.

Altium remains a solid partner to PHI, and we are confident that the rights issue will contribute to strengthening both PHI’s and shareholders' long-term value”, says Goran Dubravčić, Chairman of PHI and CEO of Altium.

Anders Månsson, new CEO of PHI, comments

“I am very excited, as the new CEO of PHI, to lead PHI through this important phase of our growth journey. The rights issue now being conducted is a strategic move to strengthen our financial position and ensure the resources needed to take the next steps in our development.

We are particularly grateful for the long-term and strong partnership with our largest shareholder, Altium, who not only is our largest shareholder but also a key partner responsible for our global distribution. Their decision to fully participate in the rights issue with a substantial investment provides us with both financial support and continued confidence in the market.

Together with our dedicated team and strategic partners, I look forward to building on the successes we have achieved so far and creating long-term value for our shareholders and customers”, says Anders Månsson, new CEO of PHI.

Summary

• The Board of Directors of PHI has resolved on the Rights Issue amounting to approximately SEK 64.3 million before deduction of issue related costs. The capitalization is intended to fund the Company's operations until at least Q1 2026 as well as strengthen the Company's capital structure by repayment/off-setting of outstanding loans leading to PHI being debt free of interest-bearing liabilities post-transaction.

• The Rights Issue is secured in writing to 100 percent through pre-subscription- and underwriting commitments, as set out below:

• • Altium has provided a pre-subscription commitment of approximately SEK 15.2 million, corresponding to approximately 23.6 percent of the Rights Issue, which is equal to Altium’s pro-rata holdings in PHI.

• • Altium has, in addition to the pre-subscription commitment, provided a top-down underwriting (from 100 percent down) commitment of approximately SEK 20.5 million, corresponding to approximately 31.8 percent of the Rights Issue, which is equal to the outstanding convertible loan amount (and its accumulated interest) held by Altium.

• • A consortium of external qualified underwriters has provided bottom underwriting commitments totalling approximately SEK 28.7 million, corresponding to approximately 44.6 percent of the Rights Issue and stems from the pre-subscribed level of 23.6 percent, up to the top-down underwriting commitment.

• The subscription price in the Rights Issue is set to SEK 1.80 per share.

• The subscription period in the Rights Issue takes place from and including 6 December 2024 until and including 20 December 2024.

• A prospectus containing complete terms and conditions for the Rights Issue will be made available no later than the day before the start of the subscription period.

Motive and use of proceeds

PHI is carrying out the Rights Issue to invest in the Company’s strategic development plan (see below) and to strengthen the Company’s capital structure. After the Rights Issue, PHI will be debt free from all interest-bearing liabilities which will put PHI in a strong position towards stakeholders such as customers, suppliers and potential external strategic investors. The Rights Issue will provide the Company with approximately SEK 64.3 million before deduction of issue related costs, which are estimated to amount to approximately SEK 9.6 million (of which approximately SEK 5.3 million refers to underwriting fees, provided that all underwriters desire to receive cash compensation).

It is the Board's assessment that the net proceeds from the Rights Issue are sufficient to finance the Company's ongoing operations and plans until at least Q1 2026.

Strategic development overview and objectives

Sales improvement initiatives – PHI recognizes the need to enhance its sales performance through more effective support for distributors. Although the current HoloMonitor® (M4) is only applicable to the pre-clinical market segment, further optimization of the sales process is expected to yield improved outcomes.

HoloMonitor® Product Line Development – PHI will continue advancing the HoloMonitor® product line, increasing the emphasis on AI support for the system, aiming to have a clinically applicable HoloMonitor® model ready by the end of 2025.

Soliciting partnerships with manufacturers – Discussions will be initiated with major manufacturers of cell processing equipment to establish a global partnership. This collaboration aims to integrate the HoloMonitor® system into larger company systems for cell processing, potentially leading to mergers and acquisitions opportunities as well as licensing agreements.

Below is a summary of the Company's objectives for the coming two years.

2025

First half-year

• Initiation of a QMS System allowing for the development of a clinical HoloMonitor® version
• The upgraded HoloMonitor® version ready for the (pre-clinical) market

Second half-year

• Initiation of development of auxiliary products to couple with the first clinical version of HoloMonitor®
• Finalization of the development of the first clinical version of HoloMonitor®
• Initiation of strategic partner discussions

2026

First half-year

• Pilot testing of the first clinical version of HoloMonitor® with real customers
• Evaluation of the pilot testing of the first clinical version of HoloMonitor®

Second half-year

• Full commercial sales of the first clinical version of HoloMonitor®
• Eligibility for a strategic partnership deal

Terms for the Rights Issue

The Board has today, subject to the approval of the extraordinary general meeting, resolved on the Rights Issue, which contains a maximum of 35,729,342 new shares. PHI’s existing shareholders have preferential rights to subscribe for shares in proportion to their existing shareholdings. The public also has the right to subscribe for shares in the Rights Issue.

One (1) existing share in the Company on the record date 4 December 2024 entitles to one (1) subscription right. Thirteen (13) subscription rights entitle the holder to subscribe for seventeen (17) new shares in PHI. The subscription price in the Rights Issue has been set to SEK 1.80 per new share.

Subscription of shares must take place during the subscription period that runs from and including 6 December 2024, until and including 20 December 2024. Subscription rights that are not exercised during the subscription period become invalid. Trading in subscription rights is expected to take place on Spotlight Stock Market from and including 6 December 2024, until and including 17 December 2024. Trading in BTA (Paid Subscribed Share) is expected to take place during the period from and including 6 December 2024, until the Rights Issue is registered with the Swedish Companies Registration Office (expected beginning of January 2025).

The Rights Issue will increase the share capital by SEK 7,145,868.40, from SEK 5,464,487.60 to SEK 12,610,356.00 and the total number of shares will increase by 35,729,342 shares, from 27,322,438 shares to 63,051,780 shares. Existing shareholders who do not participate in the Rights Issue will recognize a dilution effect of approximately 57 percent of the votes and capital, calculated on the number of shares in the Company after the Rights Issue. Shareholders who do not participate in the Rights Issue can partially compensate themselves for the financial dilution effect by selling their subscription rights no later than 17 December 2024.

Pre-subscription and underwriting commitments

The Rights Issue has been secured in writing by the main shareholder Altium and a consortium of external qualified underwriters, to a total of 100 percent, through pre-subscription and underwriting commitments. The pre-subscription commitment amounts to approximately SEK 15.2 million, which corresponds to approximately 23.6 percent of the Rights Issue, and which is equal to Altium’s pro-rata holdings in PHI. The pre-subscription will partially consist of offsetting of outstanding loans from Altium to PHI. The underwriting commitments are divided into a top-down underwriting (from 100 percent down) from Altium, amounting to approximately SEK 20.5 million, corresponding to approximately 31.8 percent of the Rights Issue and equal to the convertible loan amount (and its accumulated interest) from Altium, and a bottom underwriting tranche from external qualified underwriters totalling approximately SEK 28.7 million, corresponding to approximately 44.6 percent of the Rights Issue and stemming from the pre-subscribed level of 23.6 percent up to the top-down underwriting.

For the bottom underwriting commitment, an underwriting fee of 10 percent in cash or 13 percent in the form of newly issued shares, which are issued on the same terms as the Rights Issue, is paid. For the top-down underwriting commitment, an underwriting fee of 12 percent in cash or 15 percent in the form of newly issued shares, which are issued on the same terms as the Rights Issue, is paid. No compensation is paid for the pre-subscription commitment that has been submitted.

The pre-subscription and underwriting commitments are not secured by bank guarantee, blocking funds, pledging or similar arrangements.

Lock up

Altium has, through a lock-up agreement, with Navia Corporate Finance AB as counterparty, undertaken, with customary exceptions, not to sell any of the existing shareholding or such shareholding that is acquired through subscription in the Rights Issue, for a period of six months after the completion of the Rights Issue.

Exemption from mandatory bid

The main shareholder Altium, whose shareholdings in the Company correspond to approximately 23.6 percent of the capital and votes of PHI, has through a pre-subscription commitment undertaken to subscribe for its pro-rata part in the Rights Issue and have also entered a top-down underwriting commitment. If the underwriting commitment is fully exercised, Altium’s ownership of shares and votes in PHI will increase to over 30 percent. Altium has by the Swedish Securities Council (Swe: Aktiemarknadsnämnden) been granted exemption from the mandatory bid requirements if its shareholdings would amount to or exceed 30 percent of the number of votes in the Company because of Altium’s participation in the Rights Issue.

The exceptions are conditional upon that 1) the shareholders who will approve the Board's decision on the Rights Issue are informed of the maximum ownership of capital and votes that Altium can obtain by subscribing for shares in excess of their pro-rata part and that 2) the general meeting's decision on the Rights Issue is supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting, whereby shares held and represented at the meeting by Altium shall be disregarded. The maximum ownership of the shares and votes in PHI that Altium can receive if the top-down underwriting is fully allocated is approximately 39 percent (including Altium’s existing holdings in the Company).

Approval at the extraordinary general meeting

The extraordinary general meeting to approve the Board’s resolution on the Rights Issue is planned to be held on 2 December 2024. Notice for the extraordinary general meeting will be published via a separate press release.

Plan for incentive program

The Board of Directors plans to propose that a general meeting resolves on an incentive program for the management and other key personnel. The specific details for the planned incentive program have however not been finalized in order for the resolution to be included in the forthcoming extraordinary general meeting that is to decide on the Rights Issue.

Indicative timeline for the Rights Issue

• Last day of trading in PHI’s shares, including the right to receive subscription rights: 2 December 2024.
• First day of trading in PHI’s shares, excluding the right to receive subscription rights: 3 December 2024.
• Record date for participation in the Rights Issue: 4 December 2024.
• Approval of prospectus: 5 December 2024.
• Subscription period: 6-20 December 2024.
• Trading in subscription rights: 6-17 December 2024.
• Trading in BTA: from 6 December 2024 until the Rights Issue has been registered with the Swedish Companies Registration Office. The last day of trading in BTA will be announced through a separate press release after the Rights Issue has been completed.
• Press release on the outcome of the Rights Issue: around 23 December 2024.

Prospectus

A prospectus containing full terms and conditions for the Rights Issue will be published via a separate press release no later than the day before the subscription period begins and will be available on the Company's website (www.phiab.com) and on Spotlight Stock Market (www.spotlightstockmarket.com).

Information to investors under the Screening of Foreign Direct Investment Act (2023:560)

As the Company may conduct activities worthy of protection in accordance with the Screening of Foreign Direct Investment Act (2023:560), certain investments in the Rights Issue may require examination by the Inspectorate for Strategic Products. For more information, please visit the Swedish Inspectorate for Strategic Products' website, www.isp.se or contact the Company.

Advisors

Navia Corporate Finance AB is the financial advisor and Sole Bookrunner in connection with the Rights Issue. HWF Advokater AB is the legal advisor. Nordic Issuing AB is the issuing agent. /

Nyckelpunkter från texten :

• Företrädesemissionen är skriftligen säkerställd till 100 procent genom teckningsförbindelser och garantiåtaganden.

• Teckningskursen i Företrädesemissionen är fastställd till 1,80 SEK per aktie.
• Teckningsperioden i Företrädesemissionen löper från och med den 6 december 2024 till och med den 20 december 2024.
• Efter Företrädesemissionen kommer PHI att vara skuldfritt från alla räntebärande skulder vilket kommer att sätta PHI i en stark position gentemot intressenter såsom kunder, leverantörer och potentiella externa strategiska investerare. Företrädesemissionen kommer att tillföra Bolaget cirka 64,3 MSEK före avdrag för emissionskostnader, vilka beräknas uppgå till cirka 9,6 MSEK (varav cirka 5,3 MSEK avser garantiersättning, förutsatt att samtliga garanter önskar erhålla kontant ersättning).

• Initiativ för att förbättra försäljningen – PHI inser behovet av att förbättra sina försäljningsresultat genom effektivare stöd till distributörer. Även om den nuvarande HoloMonitor® (M4) endast är applicerbar på det prekliniska marknadssegmentet, förväntas ytterligare optimering av försäljningsprocessen ge förbättrade resultat.

  Utveckling av HoloMonitors® produktlinje – PHI kommer att fortsätta att utveckla HoloMonitor-produktlinjen®, öka betoningen på AI-stöd för systemet, med målet att ha en kliniskt tillämplig HoloMonitor-modell® klar i slutet av 2025.

  Söker partnerskap med tillverkare – Diskussioner kommer att inledas med stora tillverkare av cellbearbetningsutrustning för att etablera ett globalt partnerskap. Samarbetet syftar till att integrera HoloMonitor-systemet® i större företagssystem för cellbearbetning, vilket potentiellt kan leda till fusioner och förvärvsmöjligheter samt licensavtal.

  Nedan följer en sammanfattning av bolagets målsättningar för de kommande två åren.

  2025

  Första halvåret

  • Initiering av ett QMS-system som möjliggör utveckling av en klinisk HoloMonitor-version®
  • Den uppgraderade HoloMonitor-versionen® redo för den (prekliniska) marknaden

  Andra halvåret

  • Initiering av utveckling av hjälpprodukter för att koppla ihop med den första kliniska versionen av HoloMonitor®
  • Slutförande av utvecklingen av den första kliniska versionen av HoloMonitor®
  • Initiering av strategiska partnerdiskussioner

  2026

  Första halvåret

  • Pilottestning av den första kliniska versionen av HoloMonitor® med riktiga kunder
  • Utvärdering av pilottestningen av den första kliniska versionen av HoloMonitor®

  Andra halvåret

  • Full kommersiell försäljning av den första kliniska versionen av HoloMonitor®
  • Berättigande till ett strategiskt partnerskapsavtal